Recent Finacing
Recent Raise
Promentis Pharmaceuticals develops small-molecule therapies that engage System Xc- to modulate glutamatergic dysfunction and oxidative stress for CNS disorders including schizophrenia, Parkinson’s, and pediatric autism.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
